Cover Image
市場調查報告書

程序性細胞凋亡1配體1:開發中產品分析

Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 363583
出版日期 內容資訊 英文 158 Pages
訂單完成後即時交付
價格
Back to Top
程序性細胞凋亡1配體1:開發中產品分析 Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016
出版日期: 2016年06月22日 內容資訊: 英文 158 Pages
簡介

本報告提供以程序性細胞凋亡1配體1為標的之治療藥開發相關資訊,提供您開發階段,藥物標的,作用機制,給藥途徑及各分子類型分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

程序性細胞凋亡1配體1概要

治療藥的開發

程序性細胞凋亡1配體1:開發中的產品 - 各開發階段

計劃細胞凋亡1配體1:開發中的產品 - 各治療範圍

程序性細胞凋亡1配體1:開發中的產品 - 各適應症

程序性細胞凋亡1配體1:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

程序性細胞凋亡1配體1:企業開發中的產品

程序性細胞凋亡1配體1:大學/機關開發中的產品

程序性細胞凋亡1配體1:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

程序性細胞凋亡1配體1治療藥的開發企業

  • Abeome Corporation
  • Alnylam Pharmaceuticals, Inc.
  • AlphaMab Co., Ltd
  • AstraZeneca Plc
  • Aurigene Discovery Technologies Limited
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • CytomX Therapeutics, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genosco
  • ImmunoCellular Therapeutics, Ltd.
  • Immunocore Limited
  • IO Biotech ApS
  • Kadmon Corporation, LLC
  • MedImmune, LLC
  • Merck KGaA
  • Novartis AG
  • PsiOxus Therapeutics Limited
  • Regeneron Pharmaceuticals, Inc.
  • Shanghai Henlius Biotech Co., Ltd.
  • Sorrento Therapeutics, Inc.
  • Sutro Biopharma, Inc.
  • Theravectys SA
  • Tikcro Technologies, Ltd.
  • ViiV Healthcare Limited

藥物簡介

程序性細胞凋亡1配體1:暫停中的程序性

程序性細胞凋亡1配體1:開發中止的產品

程序性細胞凋亡1配體1:主要消息和新聞稿

附錄

目錄
Product Code: GMDHC0269TDB

Summary

Global Markets Direct's, 'Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016', provides in depth analysis on Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted pipeline therapeutics.

The report provides comprehensive information on the Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274)
  • The report reviews Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Overview
  • Therapeutics Development
    • Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Products under Development by Stage of Development
    • Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Products under Development by Therapy Area
    • Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Products under Development by Indication
  • Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Products under Development by Companies
  • Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Products under Development by Universities/Institutes
  • Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Companies Involved in Therapeutics Development
    • Abeome Corporation
    • Alnylam Pharmaceuticals, Inc.
    • AlphaMab Co., Ltd
    • AstraZeneca Plc
    • Aurigene Discovery Technologies Limited
    • BeiGene, Ltd.
    • Bristol-Myers Squibb Company
    • CytomX Therapeutics, Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Genosco
    • ImmunoCellular Therapeutics, Ltd.
    • Immunocore Limited
    • IO Biotech ApS
    • Kadmon Corporation, LLC
    • MedImmune, LLC
    • Merck KGaA
    • Novartis AG
    • PsiOxus Therapeutics Limited
    • Regeneron Pharmaceuticals, Inc.
    • Shanghai Henlius Biotech Co., Ltd.
    • Sorrento Therapeutics, Inc.
    • Sutro Biopharma, Inc.
    • Theravectys SA
    • Tikcro Technologies, Ltd.
    • ViiV Healthcare Limited
  • Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Drug Profiles
    • ALN-PDL - Drug Profile
    • Antibody to Inhibit PD-L1 for Oncology - Drug Profile
    • atezolizumab - Drug Profile
    • AUPM-327 - Drug Profile
    • avelumab - Drug Profile
    • Biologic to Inhibit PD-L1 for Immunology - Drug Profile
    • BMS-936559 - Drug Profile
    • CA-170 - Drug Profile
    • CBA-0710 - Drug Profile
    • CX-072 - Drug Profile
    • dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide - Drug Profile
    • durvalumab - Drug Profile
    • durvalumab + gefitinib - Drug Profile
    • durvalumab + IMCgp-100 + tremelimumab - Drug Profile
    • durvalumab + MEDI-0680 - Drug Profile
    • durvalumab + MEDI-6383 - Drug Profile
    • durvalumab + MEDI-9447 - Drug Profile
    • durvalumab + monalizumab - Drug Profile
    • durvalumab + tremelimumab - Drug Profile
    • GNS-1480 - Drug Profile
    • HLX-10 - Drug Profile
    • HLX-20 - Drug Profile
    • IO-103 - Drug Profile
    • KD-033 - Drug Profile
    • KN-035 - Drug Profile
    • LY-3300054 - Drug Profile
    • Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile
    • Monoclonal Antibodies to Inhibit PD-L1 for Oncology - Drug Profile
    • Monoclonal Antibodies to Inhibit PDL1 for Oncology - Drug Profile
    • Monoclonal Antibodies to Inhibit PDL1 for Oncology - Drug Profile
    • Monoclonal Antibody to Inhibit PD-L1 for Hematological Malignancies and Solid Tumors - Drug Profile
    • Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile
    • Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile
    • Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile
    • Monoclonal Antibody to Inhibit PDL-1 for Influenza - Drug Profile
    • Monoclonal Antibody to Target EGFR and Inhibit PD-L1 for Oncology - Drug Profile
    • MSB-002 - Drug Profile
    • Oncolytic Viruses to Inhibit PDL1 for Solid Tumors - Drug Profile
    • Small Molecules to Inhibit PD-L1 and PD-L2 for Oncology - Drug Profile
    • STIA-1011 - Drug Profile
    • STIA-1012 - Drug Profile
    • STIA-1014 - Drug Profile
    • STIA-1015 - Drug Profile
    • Synthetic Peptide 1 to Inhibit PD-L1 for Oncology - Drug Profile
    • Synthetic Peptide 2 to Inhibit PDL1 for Oncology - Drug Profile
    • Vaccine to Target CD274 and CD279 for Bladder Cancer - Drug Profile
    • Vaccine to Target CD274 and CD279 for Colorectal Cancer - Drug Profile
    • Vaccine to Target CD274 and CD279 for Renal Cell Carcinoma - Drug Profile
  • Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Dormant Projects
  • Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Discontinued Products
  • Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Abeome Corporation, H1 2016
  • Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016
  • Pipeline by AlphaMab Co., Ltd, H1 2016
  • Pipeline by AstraZeneca Plc, H1 2016
  • Pipeline by Aurigene Discovery Technologies Limited, H1 2016
  • Pipeline by BeiGene, Ltd., H1 2016
  • Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Pipeline by CytomX Therapeutics, Inc., H1 2016
  • Pipeline by Eli Lilly and Company, H1 2016
  • Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Pipeline by Genosco, H1 2016
  • Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2016
  • Pipeline by Immunocore Limited, H1 2016
  • Pipeline by IO Biotech ApS, H1 2016
  • Pipeline by Kadmon Corporation, LLC, H1 2016
  • Pipeline by MedImmune, LLC, H1 2016
  • Pipeline by Merck KGaA, H1 2016
  • Pipeline by Novartis AG, H1 2016
  • Pipeline by PsiOxus Therapeutics Limited, H1 2016
  • Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016
  • Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016
  • Pipeline by Sorrento Therapeutics, Inc., H1 2016
  • Pipeline by Sutro Biopharma, Inc., H1 2016
  • Pipeline by Theravectys SA, H1 2016
  • Pipeline by Tikcro Technologies, Ltd., H1 2016
  • Pipeline by ViiV Healthcare Limited, H1 2016
  • Dormant Projects, H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top